Exec Director Product Marketing

Springfield, IL (Remote)

$280K/yr – $420K/yrSenior Level12+ years expFull time

Posted 4 weeks ago

Top 1% of applicants do these two things.

The other 99% submit and hope. You're about to do something different.

Job Summary

Own the epilepsy and EMD marketing strategy with ROI-driven investments across HCP, patient, and caregiver audiences.

  • Own the 3-year plan and operating plan, guiding resource allocation and executive forecasting to hit revenue targets.
  • Lead integrated brand and omnichannel execution grounded in clinical differentiation and patient outcomes.

Job Description

Responsibilities

  • Define and lead the enterprise EMD marketing vision and strategic roadmap, with clear accountability for epilepsy performance and growth.
  • Develop and execute integrated brand strategy across epilepsy indications, including adult expansion, lifecycle innovation, and capsule formulation launch readiness and execution.
  • Own the 3-year strategic plan and annual operating plan, ensuring alignment to franchise and corporate objectives.
  • Lead prioritization, resource allocation, and investment decisions based on ROI, analytics, and enterprise trade-offs.
  • Oversee development of compelling positioning, messaging, and promotional platforms grounded in clinical differentiation and patient outcomes.
  • Drive omnichannel marketing execution across HCP, patient, and caregiver audiences, ensuring consistent and compliant delivery.
  • Partner closely with Sales, Market Access, Medical, Regulatory, Finance, and Patient Services to ensure integrated execution and performance delivery.
  • Serve as the commercial voice in executive forums (forecasting, supply, portfolio strategy), shaping decisions with data-driven insights.
  • Leverage market insights, competitive intelligence, and performance analytics to dynamically optimize strategy.
  • Establish and track KPIs to ensure accountability, continuous improvement, and delivery against revenue and share targets.
Jazz Pharmaceuticals logo

Jazz Pharmaceuticals

3.3 Glassdoor

Jazz Pharmaceuticals plc (Nasdaq: JAZZ), is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are focused on developing life-changing medicines for people with serious diseases—often with limited or no options—so they can live their lives more fully. By transforming biopharmaceutical discoveries into novel medicines, we are working to give people around the world the opportunity to redefine what’s possible – to make the “small wins” big again. Founded in 2003 and headquartered in Dublin, Ireland, Jazz Pharmaceuticals has a significant corporate presence in Palo Alto, CA and Philadelphia, PA and in England in London, Oxford and Cambridge, with manufacturing facilities in Ireland, England and Italy. We maintain a highly collaborative culture where employees focus on how they can be successful and accomplish positive results by exemplifying the company’s core values: integrity, collaboration, passion, innovation and the pursuit of excellence. Together, we are experts, analysts, specialists, advocates, scientists and professionals all with diverse backgrounds and perspectives. Working together, we are proud to support patients, innovate and bring new medicines to patients with critical unmet needs. Please see our website at www.jazzpharma.com for more information. For information on recruitment, please visit https://careers.jazzpharma.com/. For guidelines on engaging with Jazz on social media, please visit https://bit.ly/2OaMOuq.

Founded in 2003
Dublin 4, County Dublin, IRL
3.6K employees (220 in marketing)
56% recommend to a friend
66% CEO approval

Traffic Signals

Monthly Visitors
90K
Traffic Source Mix
Search
40.5%
Direct
40.2%
Referral
10.9%
Social
7.4%
Paid
0.8%

Headcount Trend

Current headcount: ~3.6K

Marketing Team

Marketing Team Size
197 (5% of company)
Marketing Roles Posted (Last 30 Days)
4

Funding

Total Funding
$2.8B
Last Raise
$850M
Post IPO Debt, 2 years ago

Funding History

  • Sep 2024
    Post IPO Debt • $850M
  • Apr 2021
    Post IPO Debt • $1.5B
  • Dec 2009
    Post IPO Debt • $120M

Recent News